Jaguar Health Inc. Announces Amendment to Existing Royalty Interest Agreement with Iliad Research, Reducing Outstanding Balance by $4.25 Million
Jaguar Health Inc. has recently entered into a significant financial agreement involving a privately negotiated exchange with Iliad Research and Trading, L.P. The agreement, known as the Iliad Series M Exchange Agreement, was finalized on June 27, 2025. As part of this arrangement, Jaguar Health issued 170 shares of Series M Perpetual Preferred Stock to Iliad, resulting in a $4,250,000 reduction in the outstanding balance of a previously established royalty interest. This move marks a strategic financial maneuver for Jaguar Health, aiming to optimize its financial obligations while maintaining operational flexibility.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-152345), on June 30, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。